Table 1 Available anti-VEGF compounds and their properties [28].
From: Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
Drug | Type of molecule | Molecular weight | Half-life in posterior segment of eye | Typical drug dosage per injection |
|---|---|---|---|---|
Bevacizumab (Avastin™) | Recombinant humanised IgG1 monoclonal antibody inhibitor of VEGF-A | 149 kDa | ~8 days | 1.25 mg in 0.05 ml |
Ranibizumab (Lucentis™) | Recombinant humanised IgG1 monoclonal antibody fragment inhibitor of VEGF-A | 48 kDa | ~5 days | 0.5 mg in 0.05 ml |
Aflibercept (Eylea™) | Decoy receptor inhibitor of VEGF-A and VEGF-B | 115 KDa | ~7 days | 2.0 mg in 0.05 ml |
